SCHEMBL10085352

SCHEMBL10085352

O=C(O)c1cc2c(F)c(F)ccc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.54
HSD17B10 Q99714 4/20 0.54
ALDH1A1 P00352 3/20 0.54
LMNA P02545 3/20 0.54
HPGD P15428 4/20 0.53
CYP2C19 P33261 2/20 0.53
PDPK1 O15530 1/20 0.53
TSHR P16473 1/20 0.53
NFKB1 P19838 1/20 0.53
APEX1 P27695 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
IDO1 P14902 3/20 0.51
TDO2 P48775 3/20 0.51
EIF4A3 P38919 1/20 0.51
RHEB Q15382 2/20 0.49
NGFR P08138 1/20 0.49
GRIN1 Q05586 2/20 0.49
MEN1 O00255 2/20 0.49
MAPK1 P28482 2/20 0.49
KMT2A Q03164 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29974441 1.00 KDM4E (0.54) KDM4EHSD17B10ALDH1A1LMNAHPGD
SCHEMBL3100612 0.83 HRH4 (0.60) KDM4EHSD17B10ALDH1A1LMNAHPGD
SCHEMBL22620683 0.83 KDM4E (0.51) KDM4EHSD17B10ALDH1A1LMNAHPGD
SCHEMBL29425136 0.83 DAO (0.58) KDM4EHSD17B10ALDH1A1LMNAHPGD
SCHEMBL1504212 0.83 HRH4 (0.59) KDM4EHSD17B10ALDH1A1LMNAHPGD
SCHEMBL6161388 0.83 DAO (0.58) KDM4EHSD17B10ALDH1A1LMNAHPGD
SCHEMBL13593174 0.81 HRH4 (0.40) KDM4EHSD17B10ALDH1A1LMNAHPGD
SCHEMBL22647484 0.80 CYP1A2 (0.46) KDM4EHSD17B10ALDH1A1LMNAHPGD
SCHEMBL22718098 0.80 EIF4A3 (0.50) KDM4EHSD17B10ALDH1A1LMNAHPGD
SCHEMBL8959744 0.80 KDM4E (0.49) KDM4EHSD17B10ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383856-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-11-21 US disclosed
US-20240376055-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-11-14 US disclosed
US-20240317708-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-09-26 US disclosed
EP-4192812-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-09-04 EP disclosed
US-20240270715-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-08-15 US disclosed
EP-4192813-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-08-14 EP disclosed
EP-4192814-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-08-07 EP disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 US disclosed
WO-2021250466-A1 SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORPORATION (CA) 2021-12-16 WO disclosed
WO-2021250461-A1 SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2021-12-16 WO disclosed
WO-2021229302-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2021-11-18 WO disclosed
EP-3873909-A1 NOVEL 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AiCuris GmbH & Co. KG (DE) 2021-09-08 EP disclosed
CN-113056467-A 6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazindole-2-carboxamide active agents against hepatitis b virus HBV 艾库里斯有限及两合公司 2021-06-29 CN disclosed
US-20210179608-A1 NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AICURIS GMBH & CO. KG (DE) 2021-06-17 US disclosed
WO-2020243135-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2020-12-03 WO disclosed
EP-3704119-A1 NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) AiCuris GmbH & Co. KG (DE) 2020-09-09 EP disclosed
CN-111527087-A Novel highly active pyrazolo-piperidine substituted indole-2-carboxamides having activity against Hepatitis B Virus (HBV) 艾库里斯有限及两合公司 2020-08-11 CN disclosed
WO-2012051708-A1 ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES, AND METHODS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210179608-A1 NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) CDK2, HCCS, BRD4 KDM4E 780/4885HSD17B10 3150/4885ALDH1A1 3842/4885
US-20240383856-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 KDM4E 967/4885HSD17B10 1094/4885ALDH1A1 1825/4885
US-20240376055-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 KDM4E 967/4885HSD17B10 1094/4885ALDH1A1 1825/4885
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 KDM4E 1496/4885HSD17B10 237/4885ALDH1A1 3140/4885
US-20240317708-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 KDM4E 967/4885HSD17B10 1094/4885ALDH1A1 1825/4885
US-20240270715-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 KDM4E 967/4885HSD17B10 1094/4885ALDH1A1 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.